Malaria vaccine candidate reduces disease over 18 months of follow-up in phase 3 children's study
Results from a large-scale Phase III trial, presented today in Durban, show that the most clinically advanced malaria vaccine candidate, RTS,S, continued to protect young children and infants from clinical malaria up to 18 ...
Oct 7, 2013